Description
Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated:
-
As a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
-
For the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma.
Dosage and Side Effects
Single agent: 60 to 75 mg/m2 given intravenously every 21 days (2.1).
In combination therapy: 40 to 75 mg/m2 given intravenously every 21 to 28 days.
Discontinue doxorubicin HCl in patients who develop signs or symptoms of cardiomyopathy. Reduce dose in patients with hepatic impairment.
The most common side effects of Doxorubicin are alopecia, nausea and vomiting.
Warning and Precautions
Radiation-induced toxicity can be increased by the administration of doxorubicin HCl. Radiation recall can occur in patients who receive doxorubicin HCl after prior radiation therapy.
Embryofetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus.
FAQ's
How should Doxorubicin be administered?
The recommended dose of doxorubicin 50 mg injection should be administered by injection into a vein.
How much does doxorubicin cost?
You can buy a doxorubicin hydrochloride injection from any authorized whole-seller after getting a prescription from a qualified doctor. The buyer should check the existing law in their home country before importing the product.
Is doxorubicin FDA approved?
Yes, Doxorubicin was approved by the FDA in 1974.
What is doxorubicin hydrochloride used for?
Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated:
-
as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
-
for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma.
